Summary
Asthma
is a common chronic inflammatory disease of the airways, characterized by
recurrent attacks of breathlessness and wheezing, which vary in frequency and
severity from patient to patient. The exact causes of asthma are currently
unknown, and may be the result of a combination of factors, although two major
factors thought to be involved are environmental exposure and host factors,
particularly genes.
Asthma
treatment can be classed as either a long-term control medication, aimed at
controlling persistent asthma, or a quick-relief medication, for the relief of
exacerbations and acute symptoms. Long-term control medication includes Inhaled
Corticosteroids (ICS), immunomodulators, leukotriene modifiers, cromolyn
sodium, nedocromil and methylxanthines. In addition, Long-Acting
Beta-Adrenoceptor Agonists (LABAs) can be used in combination with ICSs – but
not as monotherapies – for moderate or severe persistent asthma. Currently,
only one biologic – Xolair (omalizumab) – is approved as an add-on therapy for
the treatment of allergic asthma in the Asia-Pacific region. Nevertheless, significant unmet need remains
for the treatment of severe eosinophilic asthma.
View Full Report with TOC @ http://www.radiantinsights.com/research/asthma-therapeutics-in-asia-pacific-markets
Scope
The
current asthma market in the Asia-Pacific region contains novel products,
including Xolair, a recombinant humanized monoclonal anti-IgE antibody;
Seretide/Adoair, an ICS-LABA combination therapy; Relvar/Breo, an ICS-LABA
combination therapy, and Spiriva, a LAMA.
- What are the competitive advantages of the
existing novel drugs?
With
over 274 active pipeline molecules, most of the late-stage investigational drug
candidates are being evaluated, with improved dosing regimens and
administration routes in comparison to currently marketed products.
- Which classes of novel drugs are most
prominent within the pipeline?
- Is there strong potential for the pipeline
to address unmet needs within the asthma market – specifically for severe
eosinophilic asthma?
Analysis
of clinical trials since 2006 has identified that the failure rates of asthma
molecules were highest in Phase III (46%), with the overall attrition rate for
asthma in development being 78%.
Download sample Copy of This Report at: http://www.radiantinsights.com/research/asthma-therapeutics-in-asia-pacific-markets#tabs-4
- How do failure rates vary by product stage
of development, molecule type, and mechanism of action?
- How do other factors, such as average trial
duration and trial size influence the costs and risks associated with product
development?
Over
the 2014–2021 forecast period, the asthma therapeutics market in the
Asia-Pacific region is expected to increase in value at a Compound Annual
Growth Rate (CAGR) of 7.2%, from $3.5 billion to over $5.6 billion.
- Which markets make the most significant
contribution to the current market size?
- What are the epidemiology trends in these
markets?
- Will new market entrants lead to
substantial changes in annual therapy costs?
- How will different treatment usage patterns
impact growth in the five assessed Asia-Pacific markets?
Rising
asthma prevalence and uptake of newer biologics will lead to significant market
growth over the forecast period, in spite of affordability concerns.
- Will affordability threaten the commercial
success of existing drugs as well as newer biologics?
- Which of the assessed countries have
affordability concerns?
See More Reports of This Category
by Radiant Insights:
·
Asia-Pacific Sleep Apnea Diagnostic Systems Market
Outlook to 2021 - http://www.radiantinsights.com/research/asia-pacific-sleep-apnea-diagnostic-systems-market-outlook-to-2021
·
BRIC Sleep Apnea Diagnostic Systems Market Outlook
to 2021 - http://www.radiantinsights.com/research/bric-sleep-apnea-diagnostic-systems-market-outlook-to-2021
Reasons to buy
This
report will enable you to -
- Understand the clinical context of asthma
by considering symptoms, etiology, pathophysiology, epidemiology, diagnosis,
and treatment options.
- Identify the therapeutic strategies,
products, and companies that dominate the current marketed products landscape
and recognize gaps and areas of unmet need.
- Identify key pipeline trends in molecule
type, administration route, mechanism of action, and novelty.
- Consider market opportunities and potential
risks by examining trends in asthma clinical trial size, duration, and failure
rate by stage of development, molecule type, and mechanism of action.
- Recognize the late-stage pipeline molecules
that have demonstrated strong therapeutic potential in asthma by examining
clinical trial data and multi-scenario product forecast projections.
- Compare treatment usage patterns, annual
therapy costs, and market growth projections for China, India, Australia, South
Korea and Japan.
- Discover trends in licensing and
co-development deals concerning asthma products and identify the major
strategic consolidations that have shaped the commercial landscape.
About Radiant Insights
Radiant
Insights is a platform for companies looking to meet their market research and
business intelligence requirements. We assist and facilitate organizations and
individuals procure market research reports, helping them in the decision
making process. We have a comprehensive collection of reports, covering over 40
key industries and a host of micro markets. In addition to over extensive
database of reports, our experienced research coordinators also offer a host of
ancillary services such as, research partnerships/ tie-ups and customized
research solutions.
For More Information, Visit Radiant Insights
Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
Blog URL: http://www.radiantinsightsinc.blogspot.com
No comments:
Post a Comment